These experts analyse the contribution of the new antihistamine bilastine at this symposium held as part of the XXVII SEAIC Conference.
Antihistamines are are the most widely used drugs for the treatment of allergic rhinitis and urticaria. The new molecules that join this pharmacological group must meet both the efficacy, tolerability and safety requirements for any new medicinal product used as frequently in this field, and must also provide a new benefit to the therapeutic intervention in terms of improving quality of life, which is markedly affected in these patients.
